Definitive Healthcare (NASDAQ:DH) Given “Hold” Rating at Needham & Company LLC

Needham & Company LLC reaffirmed their hold rating on shares of Definitive Healthcare (NASDAQ:DH) in a research note issued to investors on Wednesday, Benzinga reports.

A number of other equities research analysts have also recently commented on the stock. Morgan Stanley cut shares of Definitive Healthcare from an overweight rating to an equal weight rating and dropped their price objective for the stock from $11.50 to $9.00 in a research note on Wednesday. Stifel Nicolaus dropped their price target on shares of Definitive Healthcare from $12.00 to $11.00 and set a buy rating on the stock in a research report on Wednesday, January 17th. Canaccord Genuity Group lifted their price objective on shares of Definitive Healthcare from $9.00 to $10.00 and gave the company a hold rating in a report on Thursday, February 29th. Finally, Barclays increased their target price on shares of Definitive Healthcare from $10.00 to $11.00 and gave the stock an equal weight rating in a research note on Friday, March 1st. Eight analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to MarketBeat, Definitive Healthcare has a consensus rating of Hold and a consensus price target of $10.81.

Definitive Healthcare Price Performance

Shares of DH opened at $5.20 on Wednesday. The firm has a market capitalization of $612.51 million, a PE ratio of -3.01, a price-to-earnings-growth ratio of 6.12 and a beta of 1.41. The company has a debt-to-equity ratio of 0.20, a current ratio of 2.31 and a quick ratio of 2.31. The company’s fifty day moving average price is $7.70 and its 200-day moving average price is $8.29. Definitive Healthcare has a 1-year low of $4.38 and a 1-year high of $12.45.

Definitive Healthcare (NASDAQ:DH) last released its earnings results on Wednesday, February 28th. The company reported ($0.01) EPS for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.02). Definitive Healthcare had a positive return on equity of 0.43% and a negative net margin of 80.40%. The firm had revenue of $65.93 million for the quarter, compared to analyst estimates of $66.01 million. On average, equities research analysts predict that Definitive Healthcare will post 0.11 EPS for the current year.

Institutional Investors Weigh In On Definitive Healthcare

Several large investors have recently bought and sold shares of DH. Conestoga Capital Advisors LLC lifted its position in shares of Definitive Healthcare by 1.3% during the 1st quarter. Conestoga Capital Advisors LLC now owns 5,595,627 shares of the company’s stock worth $45,157,000 after purchasing an additional 74,490 shares during the last quarter. Vanguard Group Inc. raised its stake in Definitive Healthcare by 6.2% in the third quarter. Vanguard Group Inc. now owns 4,331,543 shares of the company’s stock valued at $34,609,000 after buying an additional 254,726 shares in the last quarter. Massachusetts Financial Services Co. MA raised its stake in Definitive Healthcare by 76.0% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 3,466,514 shares of the company’s stock valued at $34,457,000 after buying an additional 1,496,652 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in Definitive Healthcare by 11.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 1,090,136 shares of the company’s stock worth $8,710,000 after buying an additional 113,963 shares during the last quarter. Finally, Raymond James & Associates boosted its position in shares of Definitive Healthcare by 41.6% during the 1st quarter. Raymond James & Associates now owns 844,814 shares of the company’s stock worth $6,818,000 after acquiring an additional 248,266 shares in the last quarter. Hedge funds and other institutional investors own 98.67% of the company’s stock.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.